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Results Of 164 contemporary RRSOs performed in 
78 centres, 158/159 (99%) had “adequate” surgery and 
108/164 (66%) had “adequate” pathology. Surgery per-
formed by a gynaecologic oncologist rather than a gen-
eral gynaecologist [OR 8.2, 95%CI (3.6–20.4), p < 0.001], 
surgery without concurrent hysterectomy [OR 2.5, 95%CI 
(1.1–6.0), p = 0.03], more recent year of surgery [OR 1.4, 
95%CI (1.1–1.8), p = 0.02], and clinical notation that indi-
cated high risk [OR 19.4, 95%CI (3.1–385), p = 0.008] 
were independently associated with “adequate” pathology. 
Both surgery and pathology were significantly more likely 
to be “adequate” (p < 0.001) in this contemporary sample. 
Conclusion The quality of RRSOs has significantly 
improved since our last report. Surgery by a gynaecologic 
oncologist who informs the pathologist that the woman 
is at high risk for PSC is associated with optimal RRSO 
pathology.
Abstract 
Objectives The quality of risk-reducing salpingo-oopho-
rectomy (RRSO) performed in Australasian women was 
previously reported to be suboptimal. Here we describe the 
quality of RRSO performed since 2008 in women enrolled 
in the same cohort and determine whether it has improved.
Design Prospective cohort study of women at high risk 
of pelvic serous cancer (PSC) in kConFab. Eligible women 
had RRSO between 2008 and 2014 and their RRSO sur-
gical and pathology reports were reviewed. “Adequate” 
surgery and pathology were defined as complete removal 
and paraffin embedding of all ovarian and extra-uterine fal-
lopian tube tissue, respectively. Associations between clini-
cal factors and “adequate” pathology were assessed using 
logistic regression. Data were compared with published 
cohort data on RRSO performed prior to 2008 using Chi 
square test.
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Introduction
The increased risk of invasive pelvic serous cancer (PSC) 
of the ovary, fallopian tube or peritoneum in women carry-
ing a germline mutation in the BRCA1 and BRCA2 cancer 
predisposition genes is well established, with a lifetime risk 
ranging from 31–54% and 6–27%, respectively [1–5]. The 
term “pelvic serous cancer” is used because the majority of 
BRCA1- and BRCA2-related gynaecologic cancers appear 
to originate in the fimbrial end of the fallopian tube rather 
than the ovary, although they have typically been labelled 
as “serous ovarian cancer” at diagnosis [6]. Women with 
a strong family history of “serous ovarian cancer”, but no 
identified BRCA1 or BRCA2 mutation in the family, also 
have elevated risks of PSC [7].
Given the poor prognosis of PSC and the lack of effec-
tive screening strategies [8], risk-reducing salpingo-oopho-
rectomy (RRSO) is recommended by peak bodies, such as 
the U.S. National Comprehensive Cancer Network (NCCN) 
[9] and Cancer Australia [10], for all women at high risk 
of PSC. Cancer Australia recommends consideration of 
RRSO by BRCA1 and BRCA2 mutation carriers at around 
the age of 40 years and individualised discussion for other 
women at high risk in the absence of a gene mutation [10]. 
RRSO has proven efficacy, with a reduction in “ovarian 
cancer” risk of 79–85% [11–13], and it is associated with 
lower cancer-specific and all-cause mortality in BRCA1 and 
BRCA2 mutation carriers [13, 14]. This form of surgery, as 
its names implies, incorporates the removal of both ovaries 
and fallopian tubes up to their insertion into the cornua of 
the uterus.
Despite being a prophylactic procedure, occult carci-
nomas or cancer precursor lesions such as serous tubal 
intraepithelial carcinomas (STICs) are detected in a subset 
of RRSO specimens; between 2.6–6% [15–17] and 2–8% 
[18, 19], respectively. The variability between studies 
is likely due to differences in the underlying PSC risk of 
the study participants, extent of surgery undertaken and, 
importantly, variation in the extent of pathological evalu-
ation of the RRSO specimen. The minimum pathological 
examination of RRSO specimens that might be considered 
adequate is the complete embedding of all excised ovar-
ian and fallopian tube tissue [10]. Notably, a more detailed 
pathological examination protocol, such as the SEE-FIM 
protocol, results in an approximately fourfold increase in 
detection of precursor lesions or occult carcinoma [20]. 
More recently, the use of the SEE-FIM protocol for RRSO 
specimens is recognised as the recommended standard clin-
ical practice [9].
Our previous report on RRSOs, performed in 201 Aus-
tralasian women prior to the year 2008, found 91% had 
adequate surgery and only 23% had adequate pathology 
according to the minimum definitions above [21]. Here we 
aimed to determine the quality of contemporary RRSO sur-
gery and pathology, performed between 2008 and 2014, to 
compare it with our previous findings, and to identify any 
factors associated with adequate RRSO. We hypothesised 
that, due to increased awareness of the issues discussed 
above, the adequacy of surgery and pathology would have 
improved.
Methods
Participants were a subset of females enrolled in the Kath-
leen Cuningham Foundation Consortium for Research into 
Familial Breast Cancer (kConFab), a resource of data and 
biospecimens from multiple-case breast and ovarian cancer 
families [22]. Eligibility criteria for kConFab are available 
on the website [22]. Families are recruited via 24 Family 
Cancer Clinics (FCCs) in Australia and New Zealand. At 
enrolment, blood is drawn for possible future BRCA1 and 
BRCA2 mutation analysis. Epidemiology and family his-
tory questionnaires are also completed. A mailed, self-
administered follow-up questionnaire is used to collect 
updated information on cancer events, epidemiological and 
lifestyle factors and uptake of preventative strategies on all 
female participants every 3 years [23]. Self-reported cancer 
events and surgeries, including risk-reducing surgeries, are 
verified with pathology and surgical reports obtained from 
the treating institutions. Notably, these institutions are often 
not linked with the FCC that the woman attended for her 
cancer risk assessment and genetic testing. All cohort par-
ticipants provide written informed consent and the cohort 
study has ethics approval at all recruitment sites.
Women enrolled in kConFab were eligible for this study 
if they had RRSO performed between 2008 and 2014, 
had a deleterious mutation in BRCA1 or BRCA2 or, in 
the absence of a mutation, if they had a family history of 
PSC (limited to first- or second-degree relatives). Women 
were excluded if they were non-carriers within a BRCA1 
or BRCA2 mutation-carrying family, if they had a personal 
history of gynaecological cancer or metastatic cancer or if 
their RRSO pathology report was not available.
Date of surgery, type of surgery, name of surgeon, 
whether clinical notes on the pathology report indicated the 
woman was at high risk of PSC and the extent of surgery 
and pathology were abstracted from the RRSO surgical 
and pathology reports, and supplemented by self-reported 
information from the 3-yearly follow-up questionnaire. 
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“Adequate” surgery was defined as complete removal of 
all ovarian and extra-uterine fallopian tube tissue, whilst 
“adequate” pathology was defined as paraffin embedding 
of all removed ovarian and tubal tissue. The same defini-
tion from the previous published study was used to allow 
direct comparison of the RRSO performed prior to 2008 to 
this study sample, however whether the pathology proce-
dures reported were consistent with the SEE-FIM protocol 
[20] was also recorded. The presence of occult carcinoma 
and/or STIC at RRSO was also abstracted from pathology 
reports. The duration of follow-up was calculated from the 
date of RRSO to the date of death or last contact.
Surgeon type was determined using Australian Health 
Practitioner Regulation Agency (APHRA) data [24]. Cli-
nicians were defined as general surgeons if they were 
registered fellows of the Royal Australasian College of 
Surgeons; general gynaecologists if they were registered 
fellows of the Royal Australian and New Zealand Col-
lege of Obstetricians and Gynaecologists (RANZCOG), or 
gynaecologic oncologists if they also held certification in 
gynaecologic oncology of the RANZCOG. For New Zea-
land practitioners not listed on APHRA, categorisation 
was based on information from their institutional website 
profile.
All statistical analyses were performed in R (version 
3.1.1; R Development Core Team 2009). Logistic regres-
sion was used to assess the association between adequacy 
of pathological examination of the RRSO specimen and 
the presence of clinical notes indicating high risk, year of 
surgery, surgeon type, history of breast cancer, risk sta-
tus (family history vs. BRCA mutation), type of surgery 
(abdominal vs. laparoscopic) and hysterectomy. Published 
data for 201 RRSOs, performed between 1999 and 2008 in 
women in the kConFab cohort [21], were pooled together 
with data from this study population to examine the change 
in the prevalence of “adequate” surgery and pathology over 
this whole period. Chi square test was used to compare 
categorical variables and t test was used to compare age 
between the RRSOs performed before January 1st, 2008 
and those performed after that date. All p values were two-
sided, and those less than 0.05 were considered statistically 
significant.
Results
From January 2008 to December 2014, a total of 284 
women from the kConFab follow-up study underwent 
RRSO. Of those, 120 women were excluded (37 had no 
documented gene mutation and no family history of PSC 
in a first or second-degree relative; 34 were non-carriers 
within a BRCA1 or BRCA2 mutation-carrying family; 24 
carried a variant of uncertain significance in BRCA1 or 
BRCA2; 20 had a previous history of gynaecological can-
cer or metastatic cancer; 4 carried a mutation in the p53 
or ATM genes; and for 1 the pathology report could not 
be obtained). Therefore, 164 women were eligible who 
underwent RRSO at 78 institutions across Australia and 
New Zealand; their clinical characteristics are shown in 
Table 1. Of those, 80 carried a BRCA1 mutation, 48 carried 
a BRCA2 mutation, 2 carried both a BRCA1 and a BRCA2 
mutation, and the remaining 34 had a family history of PSC 
in a first or second degree relative but no BRCA1 or BRCA2 
mutation. The median ages at RRSO for women carrying 
BRCA1 or BRCA2 mutation were 46.5 years and 46 years 
respectively. Whilst the median age at RRSO for women 
with family history of PSC was 53.5 years. Forty percent of 
women had a history of invasive breast cancer.
Surgical and pathological characteristics are detailed 
in Table  2. Most surgery was performed laparoscopically 
(74%). The majority of RRSOs were performed by gynae-
cologic oncologists (58%), or general gynaecologists 
(40%). In most cases, pathology laboratories (93%) were 
notified that this was an RRSO for a woman at high risk. 
Forty-five percent (n = 73) of the study participants had a 
Table 1  Characteristics of RRSOs performed in 2008–2014
RRSO risk-reducing salpingo-oophorectomy
Characteristic Number (%) or 
median [range]
Risk status
 BRCA1 mutation 80 (49)
 BRCA2 mutation 48 (29)
 BRCA1 and BRCA2 mutation 2 (1)
 Strong family history of ovarian cancer 34 (21)
Age at RRSO
 All participants 48.5 [30–77]
 BRCA1 mutation carriers 46.5 [32–73]
 BRCA2 mutation carriers 46 [30–77]
 BRCA1 + BRCA2 mutation carriers 39.5 [39–40]
 Strong family history of ovarian cancer 53.5 [39–70]
Location where RRSO was performed
 Australian Capital Territory 6 (4)
 New South Wales 39 (25)
 Northern Territory 1
 Queensland 17 (10)
 South Australia 36 (22)
 Tasmania 5 (3)
 Victoria 27 (17)
 Western Australia 21 (13)
 New Zealand 12 (7)
Prior history of breast cancer
 Yes 66 (40)
 No 98 (60)
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hysterectomy at the time of RRSO; of these most (n = 46) 
indicated the intention of the procedure was to reduce uter-
ine cancer risk, 11 indicated it was to treat benign issues 
such as fibroids or prolapse, 2 indicated it was because they 
planned to have tamoxifen for breast cancer treatment or 
prevention, and 14 did not provide a rationale.
All but one case (99%) were deemed to have had ade-
quate surgery, whilst 66% of the pathological evaluations 
were deemed adequate. Compared to RRSOs performed 
prior to 2008 in women enrolled in the kConFab cohort 
study, where adequate surgery occurred in 91% cases and 
adequate pathology in 23% cases [21], there was signifi-
cant improvement (p < 0.001, Fig.  1). Of note, pathology 
processing procedures consistent with the SEE-FIM proto-
col were reported in only eight cases. Personal and surgi-
cal characteristics were similar between RRSOs performed 
prior to 1st January 2008 and after, with the exception of 
the presence of clinical notes indicating high risk, which 
rose from 80 to 93% (p < 0.001, Table 3).
The one case of inadequate surgery was performed 
in 2009 by a general gynaecologist. The patient carried a 
BRCA1 mutation and she had bilateral oophorectomy but 
the left fallopian tube and part of the right fallopian tube 
were left in situ. Given that only one case had inadequate 
surgery, analysis for clinical predictors for adequate surgery 
was not undertaken.
From the multivariable model (Table  4), the pres-
ence of clinical notes to indicate the woman was high risk 
(p = 0.008), surgery performed by gynaecologic oncolo-
gist (p < 0.001), surgery without concurrent hysterectomy 
(p = 0.03), and more recent year of surgery (p = 0.02), were 
independent predictors of adequate pathology.
There were three cases (1.8%) of occult carcinoma iden-
tified at RRSO (Table 5). Two carried a BRCA1 mutation 
and one carried a BRCA2 mutation. They underwent RRSO 
at the age of 42, 53 and 63 years, respectively. No specific 
macroscopic findings were noted at surgery but micro-
scopic cancer was found on pathology. Two proceeded to 
have formal staging laparotomy and were found to have 
Stage IA (serous adenocarcinoma) and Stage IIIA (mixed 
mullerian) cancers respectively; the latter went on to have 
chemotherapy and subsequently died 5  years later. The 
patient who did not undergo formal staging laparotomy had 
poorly differentiated adenocarcinoma involving the right 
ovary without capsular breach.
There were two cases (1.2%) of STIC found at RRSO 
(Table  5), both based on morphology, and immunostain-
ing for p53 and Ki67 as recommended by Visvanathan 
et  al. [25]. The first case was a BRCA1 mutation carrier, 
age 61 years, whilst the second case was a BRCA2 mutation 
carrier, age 56 years. The foci of STIC were found at the 
fimbrial end of the fallopian tube in both cases.
The median duration of follow-up after RRSO was 
40  months (range, 1–82  months). Subsequent to RRSO, 
there was one reported case of primary peritoneal cancer 
3 years later. She carried a BRCA1 mutation and had RRSO 
performed in 2008. Surgical and pathology evaluation at 
RRSO for this case were classified as adequate according to 
the study definitions, but of note the SEE-FIM protocol was 
not used to examine the RRSO specimen.
Discussion
This is a prospective, multi-institutional study that investi-
gated the practice of RRSO in Australasian women at high 
Table 2  Surgical and pathological characteristics of RRSOs per-
formed in 2008–2014
RRSO risk-reducing salpingo-oophorectomy, STIC serous tubal 
intraepithelial carcinoma
a Five surgical reports were unavailable but in one case the hospital 
discharge summary was available and provided detail about type of 
surgery
b Five surgical reports were unavailable, but for three cases the sur-
geon name was available in self-reported information from the 
3-yearly follow-up questionnaire












 Laparoscopic converted to abdominal 5 (3)
 Vaginal 3 (2)
 Unknown 4a




 Gynaecologic oncologist 94 (58)
 General gynaecologist 65 (40)
 General surgeon 3 (2)
 Unknown 2b
Clinical notes indicating high risk on pathology report
 Yes 153 (93)
 No 11 (7)
Occult carcinoma at RRSO 3 (1.8)
Precursor lesion (STIC) at RRSO 2 (1.2)
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Fig. 1  Quality of RRSO Per-
formed in Australasian women 
at high risk of ovarian cancer 
before and after January 1st 
2008
Table 3  Comparison of 
characteristics of RRSOs 
performed before and after 1st 
January 2008
RRSO risk-reducing salpingo-oophorectomy, PSC pelvic serous cancer
Clinical variable 1998–2007 (n = 201) 2008–2015 (n = 164) p value
Risk status
 BRCA1 mutation carrier 102 (50%) 80 (49%) 0.17
 BRCA2 mutation carrier 71 (36%) 48 (29%)
 BRCA1 and BRCA2 mutation carrier 0 (0%) 2 (1%)
 Strong family history of PSC 28 (14%) 34 (21%)
Age at completion of RRSO
 Mean (SD) 48.59 (8.79) 49.01 (9.66) 0.67
 Median (range) 48 (30–77) 48.5 (30–77)
Type of surgery
 Abdominal 53 (26%) 34 (21%) 0.30
 Laparoscopic 137 (68%) 118 (74%)
Hysterectomy
 No 108 (54%) 91 (55%) 0.79
 Yes 93 (46%) 73 (45%)
Surgeon type
 General surgeon 11 (6%) 3 (2%) 0.16
 General gynaecologist 85 (42%) 65 (40%)
 Gynaecologic oncologist 105 (52%) 94 (58%)
 Unknown 0 2
Clinical notes indicating high risk
 No 37 (20%) 11 (7%) <0.001
 Yes 151 (80%) 153 (93%)
 Pathology report unavailable 13 0
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Table 4  Multivariable analysis of factors associated with adequate pathology
a Adequacy of surgeries performed by general surgeon (n = 3) and surgeries performed in 2014 (n = 2) were not assessed given small numbers
b Odds ratio per year




Adequate Inadequate OR (95% CI) p-value OR (95% CI) p value OR (95% CI) p value
History of breast 
cancer
No 67 (68%) 31 (32%) 1 1




No 1 (9%) 10 (91%) 1 1 1
Yes 107 (70%) 46 (30%) 23.3 (4.3–433) 0.003 10.5 (1.5–215.6) 0.04 19.4 (3.1–385) 0.008
Risk status Family history 16 (47%) 18 (53%) 1 1
Mutation carrier 92 (71%) 38 (29%) 2.7 (1.3–6.0) 0.01 2.9 (0.9–9.3) 0.07
Surgeon  typea General gynae-
cologist
29 (45%) 36 (55%) 1 1 1
Gynaecologic 
oncologist
79 (84%) 15 (16%) 6.5 (3.2–14.0) <0.001 11.2 (4.3–32.5) <0.001 8.2 (3.6–20.4) <0.001
Year of  surgerya 2008 26 (59%) 18 (41%) 1.20 (0.98–1.49)b 0.09 1.4 (1.0–1.8)b 0.03 1.4 (1.1–1.8)b 0.02
2009 30 (64%) 17 (36%)
2010 15 (68%) 7 (32%)
2011 15 (68%) 7 (32%)
2012 9 (64%) 5 (36%)
2013 11 (85%) 2 (15%)
Type of surgery Abdominal 18 (53%) 16 (47%) 1 1
Laparoscopic 83 (70%) 35 (30%) 2.1 (1.0–4.6) 0.06 2.1 (0.7–6) 0.17
Hysterectomy Yes 44 (60%) 29 (40%) 1 1 1
No 64 (70%) 27 (30%) 1.6 (0.8–3.0) 0.18 2.7 (1.1–7.3) 0.04 2.5 (1.1–6.0) 0.03
Table 5  Features of occult carcinomas and precursor lesions detected following RRSO





Gene mutated Surgery Pathological findings
Extend of evaluation Ovary Fallopian tube Other findings (peritoneum)
42 BRCA1 TAH + BSO Adequate 2 mm invasive 
adenocarci-
noma on right 
side
Benign Benign
53 BRCA1 BSO Adequate Benign 2 mm invasive adenocarci-
noma on left side
Small malignant deposit in 
paratubal soft tissue




Invasive tumour on left side Omental and pelvic side wall 
deposits
Benign uterus findings
No lymph node involvement 
(0/6)
Peritoneal fluid cytology 
positive for malignancy
61 BRCA1 BSO Adequate Benign STIC, focus at fimbria on 
left side
Benign
56 BRCA2 TAH + BSO Adequate Benign STIC, <1 mm at fimbria on 
left side
Benign
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risk of PSC. Overall, the quality of contemporary RRSO 
has improved significantly since the period of our previ-
ous report (p < 0.001). Reassuringly, in this contempo-
rary study, all women but 1 (99%) had adequate surgery, 
although only 66% had adequate pathological evaluation. 
The incidence of occult carcinoma (1.8%) and STICs 
(1.2%) was relatively low.
The improvement in the prevalence of adequate pathol-
ogy, to 66% from 23%, likely reflects better awareness 
among the medical community. Three modifiable clini-
cal factors were associated with adequate pathology. First, 
pathology evaluations completed on RRSOs performed by 
gynaecologic oncologists were more likely to be adequate. 
This may be related to the fact that most gynaecologic 
oncologists practice in tertiary centres where multi-disci-
plinary surgico-pathological meetings are the norm rather 
than reflecting differences in surgical expertise. Because 
of its subspecialist nature, gynaecologic oncologists usu-
ally practice in large hospitals with academic pathology 
departments or refer specimens to private laboratories with 
known gynaecological pathology expertise. Secondly, com-
munication from the surgeon to the pathology department 
that the woman was at high risk of PSC was also indepen-
dently associated with adequate pathology. Most women 
who undergo gynaecological surgery do so for benign 
gynaecologic reasons, so minimal pathology examination 
of their operative specimen sometimes occurs. Our find-
ing highlights the importance of communicating to the 
pathologist that the specimen has been taken from a woman 
at high risk. Directing the specimen to be assessed by an 
experienced gynaecologic pathologist may also facilitate 
quality pathology processing. Our finding that women who 
did not have concurrent hysterectomy were more likely to 
have adequate pathology may suggest that, when there is a 
greater load of operative specimen, examination of the cru-
cial components (tubes and ovaries) is less likely to occur. 
There remains uncertainty whether the risk of uterine can-
cer is higher than normal in mutation carriers [26, 27] and 
Australian guidelines are silent on the issue of risk-reduc-
ing hysterectomy in this setting [10]. In this study 45% of 
women having RRSO underwent concurrent hysterectomy 
and most indicated the intention of this procedure was to 
reduce uterine cancer risk.
The definition of adequate pathology in our study, 
although consistent with Cancer Australia guidelines [10], 
is very much a minimum standard for RRSO pathology 
assessment. Increasingly more detailed pathologic exami-
nation of RRSO specimens, such as the SEE-FIM protocol 
[20], is considered optimal. SEE-FIM stipulates that all 
tissue be serially sectioned and submitted and the fimbri-
ated ends of the fallopian tube are sectioned parallel to the 
long axis of the fallopian tube to maximize the exposure 
of tubal epithelium available for histological examination. 
In this study, very few RRSO specimens underwent the 
SEE-FIM protocol [20]. A finding of occult carcinoma is 
of clinical importance as it necessitates further manage-
ment to ensure complete cancer staging and consideration 
of chemotherapy, whilst clinical management of STICs is 
more controversial [18]. The clinical importance of find-
ing occult carcinoma also reinforces the commitment to 
detailed examination of the RRSO specimens in the labora-
tory. However, SEE-FIM is labour-intensive and therefore 
may be difficult to implement into practice in a nationwide 
setting. In our study, 164 RRSOs were performed at 78 
centres across Australia and New Zealand; so most centres 
performed only 1–3 of the 164 study cases each, raising the 
question of whether this type of specialised surgery and 
pathology would be better centralised in higher volume, 
tertiary or academic centres. Centralisation of care would 
also potentially provide additional advantages with respect 
to optimal management of cases with occult carcinoma and 
STICs.
The incidence of occult carcinoma and STICs in our 
study was relatively low, 1.8% and 1.2%, respectively. 
These rates may be an underestimate as one-third of cases 
had inadequate pathology and even in the cases with ade-
quate pathology, there would be variation in the extent of 
pathology assessment. One woman developed primary per-
itoneal cancer during follow-up, she was reported to have 
adequate surgery and pathology at RRSO. This is similar 
to the reported low rates in other series [12, 28]. Notably 
the median follow-up (40 months) of our study may be too 
short for cancers to manifest.
Three occult carcinomas were detected in women over 
40  years old, consistent with prior data linking increas-
ing age and risk [20]. Two cases of STICs and one case of 
occult carcinoma were found only within fallopian tubes, 
consistent with the fallopian tube being the origin for 
BRCA1 and BRCA2 mutation-associated tumours [6, 29].
Our study does have some limitations. Although the 
RRSOs and diagnoses of occult carcinomas/STICs were 
verified, we relied on the information detailed in operation 
and pathology reports to determine the adequacy of sur-
gery and pathology. In cases where there was insufficient 
detail from the surgical report, we assumed that the tissue 
received by pathologist represented the tissue removed by 
the surgeon. We did not undertake central pathology review 
of RRSO specimens. In addition, we are unable to differen-
tiate a gynae-pathologist to a general pathologist.
This multicentre study is likely to provide a true reflec-
tion of current RRSO practice for high risk women in Aus-
tralia and New Zealand. Women who elect RRSO deserve 
high quality surgery and pathology that will reduce their 
future risk of gynaecological cancer. Our study findings 
suggest that clinicians might consider referring their high 
risk women to a gynaecologic oncologist for their RRSO, 
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or at least should consider discussing the requirements for 
optimal pathology with the woman’s chosen surgeon. Sur-
geons performing RRSO should inform the pathologist 
about the intent of surgery to prompt adequate processing 
of these specimens or even consider specifying an expe-
rienced gynaecologic pathologist to examine these speci-
mens. RRSO is an effective way of preventing PSC in the 
vast majority of women who are identified to be at high risk 
of the disease, so further quality improvements should be a 
priority.
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